CION Ameerpet
Genetics · Reviewed by CION Oncologists · NABH Accredited
Risk-Reducing Hysterectomy — A Decision, Not a Recommendation
This page is about an operation performed on a woman who does not have cancer, in order that she should not develop one. That framing matters, because it makes this a genuine decision rather than a treatment plan. It works: removing the uterus, tubes and ovaries removes the endometrial and ovarian cancer risk in a way surveillance cannot match. It also costs something real, principally immediate menopause if your ovaries come out before their time. Which way that balance falls depends on your gene, your age, your family history and what you can live with. Both choosing it and declining it are reasonable, and this page tries to give you both sides properly.
- It genuinely prevents the cancers — more effectively than surveillance does
- Surgical menopause is the real cost — and it is manageable, not trivial
- HRT is usually appropriate here — the part most often left unsaid
- The gene changes the calculus — PMS2 is not MLH1
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What It Gives You and What It Costs You
Set out side by side, because a decision like this is badly served by a page that argues one way.
| Consideration | What it actually means |
|---|---|
| It removes the endometrial risk | Completely, since the organ is gone. This is the clearest benefit and it is not a partial one. Given that gynaecological surveillance has weaker evidence behind it than bowel surveillance, this closes a genuine gap. See Lynch surveillance. |
| It removes the ovarian risk | Also substantially, and this matters more than it first appears. Ovarian cancer has no effective screening test at all and tends to present late, so removing that risk is arguably the stronger half of the operation. See removing tubes and ovaries. |
| It ends the surveillance burden for those organs | No more gynaecological appointments, no more waiting for results. For women who find surveillance anxious, this is a real quality-of-life gain rather than a minor one. |
| It causes immediate menopause | The principal cost, where the ovaries are removed before natural menopause. Not a gradual transition but an abrupt one — hot flushes, sleep disruption, vaginal dryness, mood change, with longer-term effects on bone and cardiovascular health. |
| It is irreversible, and it ends fertility | Which is why the conversation happens once childbearing is complete. There is no partial version and no reversal. |
| It is surgery, with surgical risks | Small but real: bleeding, infection, injury to bladder or bowel, anaesthetic risk. Usually keyhole with a one to two night stay and around six weeks to ordinary activity. |
| It does not address the other risks | Bowel surveillance continues afterwards, as does everything else in your plan. This operation addresses the gynaecological part only. |
The point most often left unsaid: HRT is generally appropriate after this operation. For a woman who has not had cancer and has her ovaries removed before natural menopause, hormone replacement is usually recommended and is typically continued at least to the average age of natural menopause. Women frequently decline this surgery because they assume menopause must simply be endured. It should be discussed explicitly before you decide.
Did You Know? The reason this operation is discussed at all in Lynch syndrome, when preventive surgery is not offered for most cancers, comes down to a gap in what surveillance can do. For the bowel, colonoscopy removes polyps before they become cancers, so surveillance genuinely prevents disease. For the uterus and ovaries there is no equivalent — no gynaecological surveillance test has been shown to reduce deaths from endometrial cancer the way colonoscopy reduces deaths from bowel cancer. Surgery closes that gap directly. That is the honest case for it, and it is a strong one. The honest case against is that it brings on menopause early in a woman who is well. Sources: NCCN Clinical Practice Guidelines in Oncology — Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric; European Hereditary Tumour Group guidelines on Lynch syndrome; Manchester International Consensus Group recommendations.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Why Your Gene Changes the Answer
The same operation, weighed against very different levels of risk.
- MLH1 and MSH2 carry the highest risks. Both endometrial and ovarian risk are substantially elevated, so the benefit side of the ledger is at its largest and the case for surgery is correspondingly stronger.
- MSH6 carries a substantial endometrial risk. With a lower bowel risk. For MSH6 carriers the gynaecological part of the plan is relatively more important than the bowel part, which is the reverse of the usual assumption about Lynch syndrome.
- PMS2 carries meaningfully lower risks. The benefit of surgery is smaller here while the cost of early menopause is unchanged, so the balance genuinely shifts. A PMS2 carrier declining surgery is making a different decision from an MLH1 carrier declining it.
- Your age matters as much as your gene. A woman of fifty-two who is close to natural menopause faces a much smaller cost than a woman of thirty-six, for the same benefit. Timing is often the more useful lever than the yes-or-no question.
- Family history modifies both. Gynaecological cancers at young ages in your family can shift the balance regardless of gene. This is why the conversation belongs with a genetics service. See genetic counselling.
Want This Weighed Against Your Own Gene?
Genetics and gynaecological oncology together, with no pressure in either direction.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Declining This Is Also Reasonable
Surveillance and prevention are a legitimate alternative — particularly for lower-risk genes and younger women.
Questions Worth Asking Before You Decide
Five that change the shape of the decision rather than merely adding detail.
"What is my risk, for my specific gene?"
Not the risk for Lynch syndrome in general, which averages across genes with very different profiles. The figure for your variant, ideally with your family history taken into account. This single number does more to clarify the decision than anything else, and it is frequently not volunteered.
"Would HRT be appropriate for me afterwards?"
The question most often skipped, and the one that changes how the cost side looks. For a woman who has not had cancer and whose ovaries are removed before natural menopause, hormone replacement is generally recommended and typically continued at least until the average age of natural menopause. Ask specifically, before you decide rather than after.
"Could I keep my ovaries and remove only the uterus?"
A real option worth putting on the table, particularly for younger women, since it removes the endometrial risk without causing surgical menopause. It leaves the ovarian risk in place, which is the trade-off. Whether it is reasonable depends heavily on your gene and your age, and it deserves an explicit answer rather than being assumed away.
"Could I wait, and for how long?"
Timing is often more useful than the binary question. Deferring to the late forties means a much smaller menopausal cost for most of the same benefit. What matters is that deferring is a plan with a review date, not a decision quietly dropped.
"What happens to my surveillance afterwards?"
Bowel surveillance continues, and so does everything else in your Lynch plan. This operation addresses the gynaecological part only, and it is worth confirming that the rest of your schedule stays in place and whose list you remain on. See preventing Lynch cancers.
Want a Second Opinion on This Decision?
Bring your genetic report. Both sides set out properly, with no pressure either way. The opinion is free.
If You Decide to Go Ahead
What to expect, practically.
- It is usually keyhole surgery. Laparoscopic or robotic, one to two nights in hospital, and around six weeks to ordinary activity. Considerably less demanding than the same operation done for established cancer, since there is no staging to perform.
- The specimen is still examined carefully. Occasionally an unsuspected early cancer or a precancerous change is found in a uterus removed preventively. It is uncommon, it is worth knowing about in advance, and it is one reason the operation is done in a unit that can act on the finding.
- Menopause management should be arranged before, not after. If HRT is appropriate for you, having it prescribed and ready avoids weeks of unnecessary symptoms. This is the single most common practical failure after risk-reducing surgery.
- Bone and cardiovascular health need attention. Early menopause affects both. Bone density monitoring and attention to blood pressure, lipids and activity belong in your follow-up. See bone health.
- Vaginal dryness is treatable and should be raised. A common consequence of surgical menopause that goes unmentioned far too often, and one that responds well to treatment. See vaginal health.
And if you decide against it, that is a plan too rather than an absence of one. It means continuing surveillance, having any abnormal bleeding assessed promptly, and revisiting the question at intervals as your age and circumstances change.
Why This Decision Needs Two Specialties
A genetics team knows the risk. A gynaecological oncologist knows the operation. You need both in the room.
Lynch counselling built in
Tumour board for every diagnosis
Named MCh surgical oncologists
45-minute consultations
Decisions for healing, not billing
Second opinions welcomed, not resented
Take The Next Step
Ask About HRT Before You Decide
For a woman without cancer, it is usually appropriate — and assuming otherwise changes the decision wrongly.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Risk-Reducing Hysterectomy — Frequently Asked Questions
Why is preventive surgery offered for Lynch syndrome at all?
Because of a gap in what surveillance can achieve. For the bowel, colonoscopy removes polyps before they become cancers, so surveillance genuinely prevents disease and is associated with fewer bowel cancer deaths. For the uterus and ovaries there is no equivalent — no gynaecological surveillance test has been shown to reduce endometrial cancer deaths in the way colonoscopy reduces bowel cancer deaths, and ovarian cancer has no effective screening test at all. Removing the organs closes that gap directly. That is the case for the operation, and it is a genuine one; the case against is that it brings on menopause early in a woman who is well.
Will I need HRT afterwards, and is it safe?
If your ovaries are removed before natural menopause and you have not had cancer, hormone replacement therapy is generally appropriate and is usually continued at least until the average age of natural menopause. The reasoning is that you are replacing hormones your body would still have been producing, rather than adding hormones after their natural time. It matters because early menopause affects bone density and cardiovascular health as well as day-to-day wellbeing. This question is skipped surprisingly often, and women sometimes decline the surgery believing menopause must simply be endured. Ask about it explicitly before you decide, not afterwards.
Could I keep my ovaries and just remove the uterus?
It is a real option and worth raising, particularly if you are young. Removing the uterus alone eliminates the endometrial cancer risk while avoiding surgical menopause entirely, since the ovaries continue producing hormones. What it leaves in place is the ovarian cancer risk, which in Lynch syndrome is also elevated and for which there is no effective screening. Whether that trade is reasonable depends substantially on your specific gene, your age and your family history. It deserves an explicit discussion rather than being assumed away in either direction.
At what age should this be considered?
The conversation typically begins once childbearing is complete, and the timing after that is genuinely negotiable rather than fixed. The benefit is broadly constant while the cost falls sharply with age — a woman of fifty-two close to natural menopause loses much less than a woman of thirty-six, for much the same protection. Many women therefore choose to defer into their forties, continuing surveillance in the meantime. What matters is that deferring is an actual plan with a review date rather than a decision quietly allowed to lapse. Your specific gene should inform this: risks differ substantially between MLH1, MSH2, MSH6 and PMS2.
Is it wrong to decline this operation?
No. This is surgery on a healthy woman to prevent a cancer that may never occur, and declining it is a legitimate choice — particularly for carriers of lower-risk genes such as PMS2, for younger women, and for women who would find surgical menopause hard to accept. Declining is not the absence of a plan: it means continuing gynaecological surveillance, having any abnormal bleeding assessed promptly rather than waiting for an appointment, continuing bowel surveillance and other prevention, and revisiting the question periodically as your circumstances change. A good genetics service will support that choice as readily as the other one.
Medical disclaimer: This page provides general information about risk-reducing surgery in Lynch syndrome, reviewed by a CION oncologist. It is not a substitute for genetic counselling or individual medical advice. Risk-reducing hysterectomy is a preference-sensitive decision that should be made with a clinical genetics service and a gynaecological oncologist who know your specific gene, personal circumstances and family history. Decisions about hormone replacement therapy after surgery should be made with your treating doctors.